International Journal of Molecular Sciences · 2019 · 37 citations · 35 references
Life SciencesNeuroscienceOphthalmologyInflammationNeuroimmunologyOcular PharmacologyCytokine BiologyCytokine SignalingCytokine-mediated PathologyDiabetic RetinopathyNeuroinflammationOcular InflammationBlood - Retinal BarrierBlood-retinal Barrier DysfunctionBlood-retinal Barrier InflammationBlood-retinal Barrier PermeabilityMicrovascular ComplicationsRetinal Disease MechanismsRetinal Microvascular AbnormalitiesRetinal Neuroinflammation
Current treatments for diabetic retinopathy (DR) target late stages when vision has already been significantly affected. Accumulating evidence suggests that neuroinflammation plays a major role in the pathogenesis of DR, resulting in the disruption of the blood-retinal barrier. Suppressors of cytokine signaling (SOCS) are cytokine-inducible proteins that function as a negative feedback loop regulating cytokine responses. On this basis, the aim of the present study was to evaluate the effect of a SOCS1-derived peptide administered by eye drops (2 weeks) on retinal neuroinflammation and early microvascular abnormalities in a db/db mouse model. In brief, we found that SOCS1-derived peptide significantly reduced glial activation and neural apoptosis induced by diabetes, as well as retinal levels of proinflammatory cytokines. Moreover, a significant improvement of electroretinogram parameters was observed, thus revealing a clear impact of the histological findings on global retinal function. Finally, SOCS1-derived peptide prevented the disruption of the blood-retinal barrier. Overall, our results suggest that topical administration of SOCS1-derived peptide is effective in preventing retinal neuroinflammation and early microvascular impairment. These findings could open up a new strategy for the treatment of early stages of DR.
35
Standard for clinical electroretinography (2004 update)
Michael F. Marmor, Graham E. Holder, Mathias W. Seeliger et al. · Documenta Ophthalmologica · 2004 · 505 citations